Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies

Chimeric antigen receptor (CAR) T cell therapy, especially anti-CD19 CAR T cell therapy, has shown remarkable anticancer activity in patients with relapsed/refractory acute lymphoblastic leukemia, demonstrating an inspiring complete remission rate. However, with extension of the follow-up period, th...

Full description

Saved in:
Bibliographic Details
Published in:Biomark Res
Main Authors: Nie, Yuru, Lu, Weiqing, Chen, Daiyu, Tu, Huilin, Guo, Zhenling, Zhou, Xuan, Li, Meifang, Tu, Sanfang, Li, Yuhua
Format: Artigo
Language:Inglês
Published: BioMed Central 2020
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7254656/
https://ncbi.nlm.nih.gov/pubmed/32514351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-020-00197-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items